FDA_TrackerJim said:Orforglipron is the more interesting oral story because it is not a peptide at all.
I do not accept that the fasting window is a minor inconvenience. Adherence data on daily orals with timing requirements is consistently worse than weekly injections, and a drug you take imperfectly is a lower dose than the one on the box.
The figures, for anyone assembling their own picture. If you are comparing against somebody else’s result, check that you are comparing the same measurement taken the same way. Most of the apparent contradictions in these threads dissolve at that step.
PharmD_Rodriguez said:I do not accept that the fasting window is a minor inconvenience.
Adding the part of the answer the thread has not reached. Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third retelling.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsFollowing on from HPLC_Greg — and this may be the naive question:
How much of the oral variability is the SNAC absorption window and how much is dose, because the two get conflated constantly?
Closing the loop on my own question.
I moved the tablet to the moment I wake up rather than trying to fit it around breakfast, and the difference in the following weeks was obvious. It was a timing problem, not a dose problem.